Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies

Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies

Abstract Cell-based immunotherapies (CBIs), notably exemplified by chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy, have emerged as groundbreaking approaches for cancer therapy. Nevertheless, akin to various other therapeutic modalities, tumor cells employ counterstrategies to mani...

Descripció completa

Dades bibliogràfiques
Autors principals:	Yan-Ruide Li, Tyler Halladay, Lili Yang
Format:	Article
Idioma:	English
Publicat:	BMC 2024-01-01
Col·lecció:	Journal of Biomedical Science
Matèries:	Immune evasion Cell-based immunotherapies (CBIs) Chimeric antigen receptor (CAR) CAR-engineered T (CAR-T) cell therapy Tumor microenvironment (TME) Immune checkpoint proteins
Accés en línia:	https://doi.org/10.1186/s12929-024-00998-8

Ítems similars

An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy
per: Yan-Ruide Li, et al.
Publicat: (2022-05-01)

Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors
per: Abigail Cheever, et al.
Publicat: (2022-11-01)

CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review
per: Ler Yie Chan, et al.
Publicat: (2022-03-01)

Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions
per: John A. Ligon, et al.
Publicat: (2022-02-01)

The Emergence of Universal Immune Receptor T Cell Therapy for Cancer
per: Nicholas G. Minutolo, et al.
Publicat: (2019-03-01)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
per: Kevin Pan, et al.
Publicat: (2022-03-01)

Immune evader cancer stem cells direct the perspective approaches to cancer immunotherapy
per: Hassan Dianat-Moghadam, et al.
Publicat: (2022-04-01)

A Metabolism Toolbox for CAR T Therapy
per: Xuequn Xu, et al.
Publicat: (2019-04-01)

A Novel Peptide-MHC Targeted Chimeric Antigen Receptor T Cell Forms a T Cell-like Immune Synapse
per: Stacie Shiqi Wang, et al.
Publicat: (2021-12-01)

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
per: Diana Gumber, et al.
Publicat: (2022-03-01)

Immune Escape in Glioblastoma: Mechanisms of Action and Implications for Immune Checkpoint Inhibitors and CAR T-Cell Therapy
per: Catherine Yu, et al.
Publicat: (2023-12-01)

Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy
per: Laura Bracci, et al.
Publicat: (2020-10-01)

Barriers to overcoming immunotherapy resistance in glioblastoma
per: Julia S. Gillette, et al.
Publicat: (2023-05-01)

The Notch signaling pathway: a potential target for cancer immunotherapy
per: Xinxin Li, et al.
Publicat: (2023-05-01)

Harnessing natural killer cells to develop next‐generation cellular immunotherapy
per: Siyao Liu, et al.
Publicat: (2022-12-01)

Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasion to Promising Targeted Cellular Therapies
per: Erhard Hofer, et al.
Publicat: (2017-07-01)

Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma
per: Rebecca C Abbott, et al.
Publicat: (2021-01-01)

Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
per: Ali Keshavarz, et al.
Publicat: (2022-09-01)

Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies
per: Jessica Waibl Polania, et al.
Publicat: (2021-11-01)

Tumor immunotherapy: Mechanisms and clinical applications
per: Cheng Nong, et al.
Publicat: (2022-06-01)

Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing
per: Gianna M. Branella, et al.
Publicat: (2021-12-01)

Immunotherapy of glioblastoma: Recent advances and future prospects
per: Boyang Yuan, et al.
Publicat: (2022-11-01)

CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option
per: Györgyi Műzes, et al.
Publicat: (2023-06-01)

Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review
per: Vahid Moradi, et al.
Publicat: (2024-06-01)

CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy
per: Kaveh Hadiloo, et al.
Publicat: (2023-05-01)

CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors
per: Anna C. Filley, et al.
Publicat: (2018-10-01)

Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism
per: Quanjun Yang, et al.
Publicat: (2022-12-01)

Infection Temperature Affects the Phenotype and Function of Chimeric Antigen Receptor T Cells Produced via Lentiviral Technology
per: Xin Jin, et al.
Publicat: (2021-04-01)

The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook
per: Hao Zhang, et al.
Publicat: (2022-07-01)

Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases
per: Alejandrina Hernández-López, et al.
Publicat: (2025-01-01)

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
per: Hejin Jia, et al.
Publicat: (2019-06-01)

Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy
per: Bohan Zhang, et al.
Publicat: (2025-02-01)

Combining chemotherapy with CAR-T cell therapy in treating solid tumors
per: Arthur Xuan Wang, et al.
Publicat: (2023-03-01)

Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions
per: Peng Zhang, et al.
Publicat: (2022-07-01)

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy
per: Yuning Chen, et al.
Publicat: (2023-03-01)

Newest Approaches in Immunotherapy for Non-Hodgkin’s Lymphoma
per: Emily C. Ayers, et al.
Publicat: (2018-12-01)

CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours
per: Hiu Kwan Carolyn Tang, et al.
Publicat: (2023-06-01)

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma
per: Maria Giraudo, et al.
Publicat: (2024-03-01)

Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future
per: Samer A. Srour, et al.
Publicat: (2023-01-01)

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility
per: Piotr Celichowski, et al.
Publicat: (2023-03-01)